PVCT (1.06) Industry Supports International Research on New Melanoma Treatments
Friday, June 13 2008 10:25 AM, EST
Business Wire "US Press Releases "
KNOXVILLE, Tenn . & SYDNEY, Australia --(BUSINESS WIRE)--
Provectus Pharmaceuticals (OTC BB: PVCT) and the Australia and New Zealand Melanoma Trials Group (ANZMTG) have joined forces to advance cutting edge melanoma research at the University of Sydney , it was announced today.
In a new sponsorship deal announced today, US based biotechnology company Provectus Pharmaceuticals Inc. has provided funding for a research Fellowship at the ANZMTG to support essential personnel infrastructure in both Australia and New Zealand .
"The Provectus Fellowship is a unique and innovative partnership between industry and the ANZMTG, which will further the research efforts of many melanoma investigators," said Rachael Morton, Executive Officer of the ANZMTG.
The sponsorship of a new Research Fellow will enable the ANZMTG to engage a senior biostatistician who will design and analyze clinical trials for new treatments in melanoma and provides a model for future partnerships in this area.
"Provectus was attracted to Australia by its world-leading experts, facilities and history of success testing innovative therapies for melanoma. We are proud to be an active member of this vital research community and our support of the ANZMTG through this fellowship," said Craig Dees, CEO of Provectus.
Provectus has been conducting clinical testing of its lead oncology agent PV-10 in Australia since August 2005 . The global lead investigator for the Company's current phase 2 study is Professor John F. Thompson, chair of the ANZMTG and Executive Director of the Sydney Melanoma Unit.
The ANZMTG plans to commence a multi-centre trial of whole brain radiotherapy in melanoma in the next couple of months.
An official presentation, tour of facilities and interview opportunities will take place at 9.30am at the ANZMTG offices 1A Eden Street, North Sydney , on Friday 13 June.
For further information contact the Media Office on +61 2 9351 4312 or 0421 617 861.
About ANZMTG
The ANZMTG is a member of the Cooperative Clinical Trials Groups of the Clinical Oncological Society of Australia (COSA), and is funded by Cancer Australia and supported by the Melanoma Foundation of The University of Sydney . The ANZMTG was formed in 1999. Its first project was to design and support a randomized Phase III trial in melanoma comparing radiotherapy to observation in patients whose melanoma had spread to their lymph nodes. For more information contact www.anzmtg.org or email: anzmtg@usyd.edu.au
About Provectus (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com Porter, LeVay & Rose, Inc. via the information provided above.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Source: Provectus Pharmaceuticals
AI
